Story · Medicine & Biotech

Neil Vasan Highlights the Accelerated FDA Approval of Daraxonrasib Through the Priority Voucher Program

1 outlet · first reported by OncoDaily on · latest · 25 hours of coverage

Neil Vasan, Director of Breast Cancer Translational Research at NYU Langone Health, shared on X: “PDAC patients and Revolution Medicines benefited uniquely from the priority voucher program. Daraxonrasib (RASONQUE) was (OncoDaily)

Coverage, in order

  1. first OncoDaily obscure
    Neil Vasan Highlights the Accelerated FDA Approval of Daraxonrasib Through the Priority Voucher Program

    Neil Vasan, Director of Breast Cancer Translational Research at NYU Langone Health, shared on X: “PDAC patients and Revolution Medicines benefited uniquely from the priority voucher program. Daraxonrasib (RASONQUE) was

  2. OncoDaily obscure randomized trial
    NEXT Oncology Highlights Its Impact in the Daraxonrasib Journey From Phase 1 to FDA Approval

    NEXT Oncology, an Avacare business shared on LinkedIn: “In 2022, NEXT Oncology treated one of the first patients with daraxonrasib, a potentially promising treatment for pancreatic cancer. Our sites went

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.